MapLight Therapeutics (MPLT) EBIT (2024 - 2025)
MapLight Therapeutics (MPLT) reported EBIT of -$83.4 million for Q4 2025, down 266.06% on a YoY basis from $50.2 million in Q4 2024, and down 164.71% sequentially from -$31.5 million in Q3 2025.
MapLight Therapeutics (MPLT) EBIT (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of EBIT data on file, last reported at -$83.4 million in Q4 2025.
- For the quarter ending Q4 2025, EBIT fell 266.06% year-over-year to -$83.4 million; the trailing twelve-month figure through Dec 2025 stood at -$158.5 million (changed N/A YoY), and the FY2025 full-year result was -$169.1 million, down 103.85% from the prior year.
- EBIT retreated to -$83.4 million in Q4 2025, from -$31.5 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$20.9 million in Q3 2024 to a low of -$83.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | MapLight Therapeutics | 314.07 Mn | 314.07 Mn | - | -83.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -83.38 Mn |
| Sep 30, 2025 | -31.50 Mn |
| Dec 31, 2024 | -22.78 Mn |
| Sep 30, 2024 | -20.89 Mn |